Heart Failure Reviews

Heart Failure Reviews is an international review journal published by Springer since 1996 that builds a working dialogue between basic scientists and clinical investigators on the pathogenesis and treatment of heart failure, and it holds a 2025 Journal Impact Factor of 5.3《心力衰竭评论》是（Springer）自 1996 年起出版的国际综述期刊，致力于在基础科学家与临床研究者之间就心力衰竭的发病机制与治疗建立对话，2025 年影响因子为 5.3。

Scope

• Clinical approaches to heart failure, from diagnosis and risk stratification to the long term management of patients心力衰竭的临床路径，从诊断、风险分层到患者的长期管理。
• Surgical approaches to therapy and device based treatment, including the device management of heart failure with preserved ejection fraction外科治疗路径与器械治疗，包括射血分数保留型心力衰竭的器械管理。
• Basic pharmacology and the pharmacology underlying heart failure drug therapy基础药理学以及心力衰竭药物治疗所依据的药理机制。
• Biochemistry of the failing myocardium, including neurohormonal and metabolic signalling衰竭心肌的生物化学，包括神经激素与代谢信号。
• Molecular biology and the cellular mechanisms that drive remodelling and disease progression分子生物学以及驱动心室重构与疾病进展的细胞机制。
• Pathology of the myocardium and its clinical correlates心肌病理学及其临床对应表现。
• Electrophysiology, arrhythmia mechanisms and rhythm related aspects of heart failure care电生理学、心律失常机制以及心力衰竭诊疗中的节律问题。

History

• Volume 1, number 1 appeared in March 1996 under Kluwer Academic Publishers of Dordrecht, at a time when heart failure was emerging as a distinct subspecialty第 1 卷第 1 期于 1996 年 3 月由（Kluwer Academic Publishers）在荷兰多德雷赫特出版，当时心力衰竭正逐渐成为独立的亚专科。^[1]
• Kluwer's journal programme was later absorbed by Springer, which publishes the title today from New York as part of Springer Nature（Kluwer）的期刊业务其后并入（Springer），该刊现由位于纽约的（Springer）作为（Springer Nature）的一部分出版。
• It has remained a review journal throughout, filling issues with invited and submitted reviews, mini reviews, debates and primers rather than primary research papers该刊始终是综述型期刊，各期以受邀与自由投稿的综述、小型综述、辩论与入门述评为主，而非首发研究论文。
• It appears six times a year, in January, March, May, July, September and November, reaching volume 30 in 2025 and opening volume 31 in 2026该刊每年出版 6 期，分别在 1 月、3 月、5 月、7 月、9 月与 11 月，2025 年出至第 30 卷，2026 年进入第 31 卷。
• Its Journal Impact Factor stood at 4.214 in 2021, 4.654 in 2022, 4.2 in 2024 and 5.3 in 2025其影响因子 2021 年为 4.214，2022 年为 4.654，2024 年为 4.2，2025 年为 5.3。
• It ranks in the first quartile of cardiac and cardiovascular systems, at 50 of 237 titles in 2025, and drew about 914,600 downloads in that year该刊在心脏与心血管系统类别以 50/237 位列第一四分位，2025 年下载量约 91.46 万次。

Editors

• Andrew P. Ambrosy, a heart failure clinician investigator at Kaiser Permanente Northern California in the United States, is editor-in-chief主编为（Kaiser Permanente Northern California）的 Andrew P. Ambrosy，从事心力衰竭临床研究。
• Sidney Goldstein and Hani N. Sabbah, both long associated with Henry Ford Hospital in Detroit, edited the journal before him其前任主编为 Sidney Goldstein 与 Hani N. Sabbah，二人长期任职于底特律的（Henry Ford Hospital）。
• Springer has opened a search for the next editor-in-chief, whose term is to begin in 2027（Springer）已启动下一任主编的遴选，任期自 2027 年起。
• The journal commissions thematic collections, recent ones covering heart failure with preserved ejection fraction, cardiac amyloidosis, device treatment and late breaking trials reported at cardiology congresses该刊组织专题合集，近期主题包括射血分数保留型心力衰竭、心脏淀粉样变、器械治疗以及心脏病学大会上的最新突破性试验。
• Every review is peer reviewed before publication, and the median time from submission to first decision is three days所有综述发表前均经同行评审，从投稿到首次决定的中位时间为 3 天。
• Articles are published under a hybrid model, so authors may follow the subscription route or pay for immediate open access文章采用混合出版模式，作者可选择订阅路径，或支付费用以立即开放获取。